Loading
A phase 3 trial of Sotorasib, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Amgen, now recruiting.
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) is a phase 3 interventional study registered as NCT05920356 by Amgen, with 750 participants planned, started 2023-11-16 and due to reach its primary completion in 2027-06-30. Interventions recorded: Sotorasib, Pembrolizumab. Conditions listed: Non-Small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Amgen, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares Sotorasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Small-cell lung cancer.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Small-cell lung cancer, Pembrolizumab.
Shares Amgen, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Small-cell lung cancer, Pembrolizumab.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Small-cell lung cancer, Pembrolizumab.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Pembrolizumab, Immune checkpoint inhibitors.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Small-cell lung cancer, Pembrolizumab.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/